BioAsset

Insights / All articles

Company Analysis

The Quiet (and Growing) Giant of US Healthcare: Cardinal Health

By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 7 slides

Cardinal Health is one of the three largest drug distributors in the country, and it moves almost entirely unnoticed. It is the middleman behind your prescriptions, earning pennies per dollar on billions per year. Its fiscal 2025 revenue was $222.6B, more than twice Johnson & Johnson’s revenue and more than twice Walgreens’ pharmacy sales.

In US healthcare, the spotlight usually falls on drugmakers (Johnson & Johnson, Merck, Eli Lilly), pharmacies (CVS, Walgreens) and insurers (UnitedHealth, Aetna, Cigna). They get the most attention and the most controversy, and most people assume they also bring in the most money. Johnson & Johnson had $94.2B in 2025 revenue, Walgreens about $89B in U.S. pharmacy sales in fiscal 2024, and UnitedHealth Group $447.6B in 2025, nearly 5x J&J. The company that actually makes the medicine isn’t the one bringing in the most money.

Between them sits the distributor. Ozempic doesn’t travel from Novo Nordisk’s plant to the CVS fridge by itself. About 16 million U.S. adults use prescription stimulants like Adderall each year, and every one of those controlled-substance fills passes through a middleman. Even a basic generic like rosuvastatin takes the same route. Brand, generic or controlled substance, Cardinal buys it, stores it and delivers it, and takes a cut along the way. It is part of the reason millions of Americans can pick up their prescriptions every day.

Following the money

Drugs move from manufacturer to distributor to pharmacy to patient. Money moves back the other way, with insurance paying the pharmacy alongside the patient’s co-pay. Without the distributor, the flow is broken.

How much each party really makes is harder to see, because contracts and rebates are confidential. This estimate is based solely on published industry averages, in this case for Zepbound.

The patient pays a $25 copay at the pharmacy, plus an insurance premium that varies. The pharmacy buys its inventory from the wholesaler for $995, and the wholesaler buys the drug from the manufacturer for $975. Insurers do not deal directly with drugmakers or pharmacies. They hire a pharmacy benefit manager (PBM), so the insurer sends the PBM $975 in claim funding and the PBM reimburses the pharmacy $975. The manufacturer pays the PBM a $400 rebate, of which $380 goes on to the insurer.

After rebates, the manufacturer has $575 in revenue before costs. The wholesaler’s gross spread is $20 and the pharmacy’s is $5, neither of which is profit. The PBM retains $20 of the rebate, also not profit, and the insurer’s net drug cost is $595.

The manufacturer and the insurer look like they make the most from the sale of one Zepbound product, and in the end the insurer does. The manufacturer only makes money when its own drug is the one being sold. If it’s Novo Nordisk’s Ozempic, Eli Lilly makes nothing and Novo does. Cardinal Health, CVS, UnitedHealth and the PBMs still get their cut.

At the end of the day, it’s all about the competition. There are about 18 large-cap drugmakers ($10B+ market cap). In distribution, the big three (Cardinal Health, McKesson and Cencora) account for 96% of the market, on PCMA-reported share for 2026. In pharmacies, CVS Health had 14.7% of 2024 dispensing revenue and Walgreens 14.6%, with other companies at 70.7%. In health insurance, UnitedHealth had 16% of 2024 commercial enrollment, Elevance and CVS/Aetna 12% each, Cigna 9% and HCSC 8%, with other insurers at 43%.

The finances

According to studies and publicly released material, distributors like Cardinal Health make significantly more money selling generic drugs than brand names. They can make about 15-50% profit on a generic because of its low price, against about 1% on an expensive brand-name drug.

In its latest full year, fiscal 2026 (ended June 30), Cardinal’s revenue rose 14% to $254.2 billion, mostly from selling more branded and specialty drugs to new and existing customers. Drug distribution made up about 92% of that, at $234.8 billion, up 15%. Medical products were about 5%, at $12.7 billion, up 1%, and smaller growth businesses about 3%, at $6.8 billion, up 26%.

What Cardinal keeps is very little per dollar. Of every $100 that comes in, about $96 goes straight back out to pay for the drugs and products it bought. About $3.86 is left as gross profit (full-year gross margin was $9.8 billion, up 20%), and $1 to $1.40 remains after paying for warehouses, trucks and staff.

Why Cardinal and not McKesson

Cardinal isn’t even the biggest distributor. McKesson has almost double its market cap (about $100B vs. about $50B) and brings in about 1.5x more a year. But Cardinal is the one that’s moving. Its revenue grew 14% against McKesson’s 12%, and its adjusted EPS grew 37% against McKesson’s 18%. Since 2022, Cardinal’s adjusted EPS has more than doubled, from $5.07 to $11.26, and its market cap has roughly tripled, from about $14B to about $50B.

McKesson is the quiet giant everyone in the industry already respects. Cardinal is the quiet giant the market just started paying attention to, and that’s why it’s worth watching.

Cardinal’s plans for the future:

The past year

Cardinal Health (NYSE: CAH) closed at $237.57 on Oct 9, up 53.96%, or $83.26, over the past year. On normalized earnings per share, it beat estimates in all four quarters of fiscal 2026, by $0.38, $0.26, $0.38 and $0.18. The estimate for the first quarter of fiscal 2027, due Nov. 5, is $2.94.

Morgan Stanley raised its price target to $265 from $255 and kept its Overweight rating, and JPMorgan moved its target to $260 from $215 while maintaining a Neutral rating. Wells Fargo raised its outlook, citing broad business strength, and Citi kept its Buy rating. Another headline reported Bank of America purchasing 2,900,596 Cardinal Health shares, and Cardinal entered into a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.